Product Name | NebuSelect™ Recombinant Human EPHB2, His-tag |
---|---|
Catalog Number | NBL-240710 |
Alias/Synonyms | EPHB2; DRT; ERK; HEK5; TYRO5; CAPB; EK5; EPHT3; PCBC; Cek5; EphB2; EPHT3MGC87492; Nuk; Qek2; Sek3 |
Appearance | see COA |
Molecule Weight | Val19-Leu543 |
CAS | N/A |
Solubility | Water Soluble |
Storage | Short term 4℃; Long term -20℃. |
Shelf Life | 2 years |
Additional info 1 | P29323-1 |
Additional info 2 |
Catalog Numbe | Size | Price | Inventory Level | |
NBL-240710-100ug | 100ug | Inquire | Inquire | |
NBL-240710-1mg | 1mg | Inquire | Inquire | |
NBL-240710-Customized Size | N/A | Inquire | Inquire |
Product Name:
NebuSelect™ Recombinant Human EPHB2, His-tag
Catalog#:
NBL-240710
Description:
NebuSelect™ Recombinant Human EPHB2, His-tag(Cat#NBL-240710) is expressed in HEK293 with His tag at the C-Terminus.It contains Val19-Leu543.
Species:
Human
Expression System:
HEK293
Molecular Weight:
The protein has a predicted MW of 59.2 kDa. Due to glycosylation, the protein migrates to 65-75 kDa based on Bis-Tris PAGE result.
Target Name:
EPHB2; DRT; ERK; HEK5; TYRO5; CAPB; EK5; EPHT3; PCBC; Cek5; EphB2; EPHT3MGC87492; Nuk; Qek2; Sek3
Target Information:
EphB2, a receptor tyrosine kinase for ephrin ligands, is overexpressed in various cancers and plays an important role in tumor progression. EPHB2 promotes endothelial-mesenchymal transition (EMT) and elicits associated pathologic characteristics of glioblastoma multiforme (GBM) such as invasion and migration. EPHB2 is epigenetically overexpressed in hypoxia, a condition highly prevalent in malignancy. Furthermore, HIF-2α is required for EPHB2 stabilization by hypoxia.
Amino Acid Sequence:
Val19-Leu543
Purity:
>95%
Formulation:
see COA
Endotoxin:
<1EU/ug(LAL Method)
Storage:
4°C for short term.
-20°C for long term.
To get more information, please contact us freely.